PDGF-A, PDGF-B, TGFbeta, and bFGF mRNA levels in patients with essential thrombocythemia treated with anagrelide.
Plasmatic levels of PDGF-AB, TGFbeta1, and bFGF are increased in patients with essential thrombocythemia (ET) while intraplatelet levels are low for PDGF, normal for TGFbeta, and elevated for bFGF. To evaluate the contribution of gene expression to the dysregulated cytokine levels, we studied platelet PDGF-A, PDGF-B, TGFbeta1, and bFGF mRNA in ET patients before and during anagrelide treatment. We found decreased PDGF-A and PDGF-B, increased TGFbeta1, and normal bFGF mRNA levels. During treatment, mRNA levels remained decreased for PDGF-A, were increased for PDGF-B and normal for TGFbeta1. In untreated patients, protein expression of PDGF paralleled its mRNA levels while different patterns of RNA and protein were found for TGFbeta1 and bFGF.
Lev
Paola R
PR
Sección Hematología Investigación, Instituto de Investigaciones Médicas Alfredo Lanari, Facultad de Medicina,Universidad de Buenos Aires, Buenos Aires, Argentina.
Salim
Juan P
JP
Kornblihtt
Laura I
LI
Pirola
Carlos J
CJ
Marta
Rosana F
RF
Heller
Paula G
PG
Molinas
Felisa C
FC
D001792:Blood Platelets / Q000737:chemistry; D016222:Fibroblast Growth Factor 2 / Q000235:genetics; D006133:Growth Substances / Q000235:genetics*; D006801:Humans; D008875:Middle Aged; D010982:Platelet-Derived Growth Factor / Q000235:genetics; D020574:Proto-Oncogene Proteins c-sis / Q000235:genetics; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000032:analysis / Q000097:blood / Q000187:drug effects*; D013920:Thrombocythemia, Essential / Q000097:blood* / Q000188:drug therapy*; D016212:Transforming Growth Factor beta / Q000235:genetics
D006133:Growth Substances; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011799:Quinazolines; D012333:RNA, Messenger; D016212:Transforming Growth Factor beta; C075278:platelet-derived growth factor A; D016222:Fibroblast Growth Factor 2; C021139:anagrelide